Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma

Takahiro Einama, Hirofumi Kamachi, Hiroshi Nishihara, Shigenori Homma, Hiromi Kanno, Kenta Takahashi, Ayami Sasaki, Munenori Tahara, Kuniaki Okada, Shunji Muraoka, Toshiya Kamiyama, Yoshihiro Matsuno, Michitaka Ozaki, Satoru Todo

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma. Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50% of tumor cells and/or moderate to strong staining, or low-level expression otherwise. Results: A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062). Conclusions: This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.

Original languageEnglish
Pages (from-to)1276-1282
Number of pages7
JournalPancreas
Volume40
Issue number8
DOIs
Publication statusPublished - 2011 Nov 1
Externally publishedYes

Fingerprint

Adenocarcinoma
Neoplasms
mesothelin
Blood Vessels
Staining and Labeling
Neoplasm Metastasis
Recurrence

Keywords

  • CA125
  • co-expression of mesothelin and CA125
  • mesothelin
  • pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. / Einama, Takahiro; Kamachi, Hirofumi; Nishihara, Hiroshi; Homma, Shigenori; Kanno, Hiromi; Takahashi, Kenta; Sasaki, Ayami; Tahara, Munenori; Okada, Kuniaki; Muraoka, Shunji; Kamiyama, Toshiya; Matsuno, Yoshihiro; Ozaki, Michitaka; Todo, Satoru.

In: Pancreas, Vol. 40, No. 8, 01.11.2011, p. 1276-1282.

Research output: Contribution to journalArticle

Einama, T, Kamachi, H, Nishihara, H, Homma, S, Kanno, H, Takahashi, K, Sasaki, A, Tahara, M, Okada, K, Muraoka, S, Kamiyama, T, Matsuno, Y, Ozaki, M & Todo, S 2011, 'Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma', Pancreas, vol. 40, no. 8, pp. 1276-1282. https://doi.org/10.1097/MPA.0b013e318221bed8
Einama, Takahiro ; Kamachi, Hirofumi ; Nishihara, Hiroshi ; Homma, Shigenori ; Kanno, Hiromi ; Takahashi, Kenta ; Sasaki, Ayami ; Tahara, Munenori ; Okada, Kuniaki ; Muraoka, Shunji ; Kamiyama, Toshiya ; Matsuno, Yoshihiro ; Ozaki, Michitaka ; Todo, Satoru. / Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. In: Pancreas. 2011 ; Vol. 40, No. 8. pp. 1276-1282.
@article{9e794918dc5b4dd3807b8afc1ba397e3,
title = "Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma",
abstract = "Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma. Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50{\%} of tumor cells and/or moderate to strong staining, or low-level expression otherwise. Results: A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062). Conclusions: This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.",
keywords = "CA125, co-expression of mesothelin and CA125, mesothelin, pancreatic ductal adenocarcinoma",
author = "Takahiro Einama and Hirofumi Kamachi and Hiroshi Nishihara and Shigenori Homma and Hiromi Kanno and Kenta Takahashi and Ayami Sasaki and Munenori Tahara and Kuniaki Okada and Shunji Muraoka and Toshiya Kamiyama and Yoshihiro Matsuno and Michitaka Ozaki and Satoru Todo",
year = "2011",
month = "11",
day = "1",
doi = "10.1097/MPA.0b013e318221bed8",
language = "English",
volume = "40",
pages = "1276--1282",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma

AU - Einama, Takahiro

AU - Kamachi, Hirofumi

AU - Nishihara, Hiroshi

AU - Homma, Shigenori

AU - Kanno, Hiromi

AU - Takahashi, Kenta

AU - Sasaki, Ayami

AU - Tahara, Munenori

AU - Okada, Kuniaki

AU - Muraoka, Shunji

AU - Kamiyama, Toshiya

AU - Matsuno, Yoshihiro

AU - Ozaki, Michitaka

AU - Todo, Satoru

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma. Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50% of tumor cells and/or moderate to strong staining, or low-level expression otherwise. Results: A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062). Conclusions: This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.

AB - Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma. Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50% of tumor cells and/or moderate to strong staining, or low-level expression otherwise. Results: A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062). Conclusions: This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.

KW - CA125

KW - co-expression of mesothelin and CA125

KW - mesothelin

KW - pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=80054861821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054861821&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e318221bed8

DO - 10.1097/MPA.0b013e318221bed8

M3 - Article

VL - 40

SP - 1276

EP - 1282

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 8

ER -